Effectiveness and safety of traditional Chinese medicine in the treatment of steroid-osteonecrosis of femoral head
A protocol for systematic review and meta-analysis

Peilin He, MD\textsuperscript{a}, Junming Chen, MD\textsuperscript{a}, Chen Yue, MD, PHD\textsuperscript{b}, Maokia Ma, MD\textsuperscript{b}, Zhenqiang Hong, MD\textsuperscript{a}, Youwen Liu, MD, PHD\textsuperscript{b,c,}\textsuperscript{*}

Abstract

Background: Osteonecrosis of the femoral head (ONFH) is a common refractory disease in orthopedics. Overdose glucocorticoid application is a common trigger for ONFH. Traditional Chinese medicine (TCM), as a treatment for ONFH, has been shown to be effective in treating steroid-induced ONFH (SONFH). However, a systematic review and meta-analysis of them is lacking. We aim to systematically review the effectiveness and safety of TCM in the treatment of SONFH.

Methods: We will search the following databases: PubMed, Embase, the Cochrane Library, MEDLINE, the Chinese Biomedical Literature Database, China Science and Technology Journal Database, China National Knowledge Infrastructure, and Wanfang Data (since the inception of the databases to the present). In addition, we will look for clinical trial registrations, prospective grey literature, relevant conference papers, and established study reference lists. We will use Review Manager 5.3 software for meta-analysis and heterogeneity assessment. We will evaluate the quality of the evidence using a hierarchy of recommendation assessment, development, and evaluation.

Results: This study will systematically evaluate the efficacy and safety of TCM in the treatment of SONFH.

Conclusion: This systematic review to evaluate the effectiveness and safety of TCM in the treatment of SONFH will provide updated evidence for clinical application.

INPLASY registration number: INPLASY202170015.

Abbreviations: GCs = glucocorticoids, ONFH = osteonecrosis of the femoral head, SONFH = steroid-induced osteonecrosis of the femoral head, TCM = traditional Chinese medicine.

Keywords: protocol, steroid-induced osteonecrosis of the femoral head, systematic review, traditional Chinese medicine

1. Introduction

Osteonecrosis of the femoral head (ONFH) is a common and refractory disease in orthopedics.\textsuperscript{1,2} Excessive glucocorticoids (GCs) are a common cause of ONFH, and steroid-induced ONFH (SONFH) occurs in more than 40\% of individuals who chronically overdose on GCs.\textsuperscript{3} SONFH occurs mainly in the young and middle-aged, aged 20 to 50 years, and without effective intervention, most patients develop femoral head collapse within 1 to 3 years after onset and have to undergo premature total hip arthroplasty.\textsuperscript{4} Clinical medical researchers believe that SONFH is a complication of hormone use, because long-term hormone use leads to poor body function, decreased circulatory system function, and slow blood flow, thus patients recover slowly and require a long treatment period, and the incidence of SONFH is significantly higher than that of traumatic osteonecrosis.\textsuperscript{5–10} To date, no specific drug has been developed clinically for the treatment of SONFH. In recent years, traditional Chinese medicine (TCM) has played an important role in the treatment of orthopedic diseases.\textsuperscript{11–13} There have been increasing numbers of clinical studies on SONFH prevention and treatment with TCM, and the efficacy is significant.\textsuperscript{14–16} It has been found clinically that TCM can achieve good results in SONFH treatment, and the results of a large number of animal experimental studies have shown that enhanced TCM use has good effects in SONFH treatment.\textsuperscript{17,18}
There remains a lack of relevant systematic reviews in clinical practice, and the purpose of this protocol is to evaluate the efficacy and safety of TCM on SONFH based on the current studies.

2. Methods

2.1. Study registration

This protocol is registered with INPLASY (INPLASY202170015), which is based on the preferred reporting items for systematic review and meta-analysis protocol guidelines.[19,20]

2.2. Ethics and dissemination

Because the program does not require patient recruitment or the collection of personal information, no further ethical approval is required.

2.3. Inclusion criteria

2.3.1. Types of studies. The included studies will be random-ized controlled trials. There will be no restrictions on language or publication type. Nonrandomized clinical studies, quasi-ran-domized controlled trials, cellular experiments, animal experi-ments, cluster randomized controlled trials, and case reports will be excluded.

2.3.2. Types of participants. The analysis will include partic-ipants who meet the diagnostic criteria for SONFH. All eligible study participants, regardless of age, race, or sex, will be included in this meta-analysis. Pregnant women, lactating women, and patients with severe diseases will be excluded.

2.3.3. Types of interventions. Patients in the experimental group should have received TCM treatment alone or in combination with other treatment modalities. The species and combination methods of the TCM will not be considered. Patients in the control group will have received non-TCM treatments.

2.3.4. Types of outcome measures

2.3.4.1. Primary outcomes. Overall efficiency, hip pain score (visual analog scale score), and hip function (Harris score, WOMAC score, etc) will be the main outcomes.

2.3.5. Secondary outcomes.

1. Total hip replacement rate;
2. Progression rate of imaging staging of femoral head necrosis (staging methods: FICAT, ARCO, Japanese Joint Society staging);
3. Percentage of the volume of the femoral head necrosis.

2.4. Database search strategy

Electronic databases and other sources, including PubMed, Embase, the Cochrane Library, MEDLINE, the Chinese Biomedical Literature Database, China Science and Technology Journal Database, China National Knowledge Infrastructure, and Wanfang Data, will be searched using computer and manual methods. Different search methods will be adjusted according to different Chinese and English databases. We will briefly describe the search process for PubMed (Table 1).

2.5. Data management selection process and data items

Two researchers will independently search all relevant literature, first reading the titles and abstracts of the literature to eliminate duplicate content. Eligible studies will then be imported into EndNoteX8 software for management. Finally, the full text will be read to identify eligible studies. If any disputes arise, the 2 researchers will discuss and reach an agreement. When a consensus cannot be reached, disagreements will be resolved with the assistance of a third investigator. If any literature is found to be missing, it will be added by contacting the original author. The study selection process will strictly follow the PRISMA flowchart. (Fig. 1).

Two researchers will independently complete the research assessment based on the eligibility assessment form and extract general information about the selected articles. Included information will be first author, sex, publication year, country, study design, sample size, detailed interventions, safety, out-comes, disease duration, and follow-up time. The above information will be repeatedly reconciled by 2 investigators, and conflicts regarding data extraction will be resolved by consensus.[21,22]

2.6. Risk of bias will be assessed in the included studies

Two investigators will assess the risk of bias based on the Cochrane Handbook for systematic reviews 5.3 (https://www.cochrane.org/). Recommended assessment tools will independently assess methodological quality. In case of disagreement, this
will be resolved by discussion between the 2 reviewers or with the assistance of a third investigator.

### 2.7. Statistical analysis methods

We will use RevMan 5.3, provided by the Cochrane Collaboration, for data analysis. We will use the Chi-square test and $I^2$ statistic to determine heterogeneity between studies. We consider heterogeneity between studies to be low when $P \geq .05$ and $I^2 \leq 50\%$. We will use fixed-effects models for the statistics. When $P < .05$ and $I^2 > 50\%$, we will consider the heterogeneity between studies to be high. We will use a random-effects model for the statistics. All data analyses will be conducted with 95% confidence intervals. Continuous data will be analyzed as the mean difference or the normalized mean difference, whereas dichotomous data will be examined as the relative risk. When $P < .05$, it indicates that the difference is statistically significant. If the heterogeneity between studies is high, we will perform subgroup analysis on different herbal medicines to explore whether herbal medicines cause heterogeneity. In addition, a sensitivity analysis will be performed if necessary.\[23\]

### 2.8. Assessment of reporting biases

If the number of included studies exceeds 10, we will use funnel plots to measure publication bias. The results of the funnel plot will also be interpreted in detail.
3. Discussion

SONFH is one of the most difficult diseases to cure in orthopedics. Many patients with ONFH eventually require hip replacement because of irreversible collapse of the femoral head, increased pain, and hip dysfunction. The prevalence of SONFH can reach 9% to 40% in patients receiving long-term and excessive hormone therapy, and its main prevalent population consists of the young and middle-aged. In most cases, the disease affects both femoral heads at the same time, leading to a high rate of disability and causing great difficulties for families and society. GCs are widely used in medical procedures because they are inexpensive and effective, but they also have side effects that must be considered. Many patients suffer irreversible damage to the femoral head because of overdose or prolonged use of glucocorticosteroids, which can have a significant impact on patients.

In recent years, an increasing number of studies have demonstrated the effectiveness and safety of TCM in the treatment of SONFH, but high-quality systematic and scientific evaluations are lacking. The purpose of this study will be to evaluate the effectiveness and safety of TCM in the treatment of SONFH. In addition, we hope to promote the development and application of TCM for the benefit of patients.

Author contributions

Conceptualization: Peilin He, Youwen Liu.
Data curation: Peilin He, Junming Chen, Chen Yue, Maoxiao Ma, Zhenqiang Hong, Youwen Liu.
Formal analysis: Peilin He, Junming Chen, Chen Yue.
Methodology: Peilin He, Junming Chen, Chen Yue.
Project administration: Youwen Liu.
Supervision: Youwen Liu.
Writing – original draft: Peilin He, Junning Chen.
Writing – review & editing: Peilin He, Junming Chen, Chen Yue, Maoxiao Ma, Zhenqiang Hong, Youwen Liu.
Conceptualization: Peilin He, Youwen Liu.
Data curation: Peilin He, Junming Chen, Chen Yue, Maoxiao Ma, Zhenqiang Hong, Youwen Liu.
Methodology: Peilin He, Junming Chen, Chen Yue.
Project administration: Youwen Liu.
Supervision: Youwen Liu.
Writing – original draft: Peilin He, Junning Chen.
Writing – review & editing: Peilin He, Junming Chen, Chen Yue, Maoxiao Ma, Zhenqiang Hong, Youwen Liu.

References

[1] Tucker A, Arbog D, König DP. Atraumatic femoral head necrosis in adults. Dtsch Arztebl Int 2016;113:31–8.
[2] Xie K, Mao Y, Qu X, et al. High-energy extracorporeal shock wave therapy for nontraumatic osteonecrosis of the femoral head. J Orthop Surg Res 2018;13:25.
[3] Liu LH, Zhang QY, Sun W, et al. Corticosteroid-induced osteonecrosis of the femoral head: detection, diagnosis, and treatment in earlier stages. Chin Med J (Engl) 2017;130:2601–7.
[4] Kubo T, Ueshima K, Saito M, et al. Clinical and basic research on steroid-induced osteonecrosis of the femoral head in Japan. J Orthop Sci 2016;21:407–13.
[5] Zhang Z, Jin A, Yan D. MicroRNA-206 contributes to the progression of steroid-induced avascular necrosis of the femoral head by inducing osteoblast apoptosis by suppressing programmed cell death 4. Mol Med Rep 2018;17:801–8.
[6] Feng Z, Zheng W, Tang Q, et al. Fludarabine inhibits STAT1-mediated up-regulation of caspase-3 expression in dexamethasone-induced osteoblasts apoptosis and slows the progression of steroid-induced avascular necrosis of the femoral head in rats. Apoptosis 2017;22:1001–12.
[7] Guerado E, Caso E. The physiopathology of avascular necrosis of the femoral head: an update. Injury 2016;47:516–26.
[8] Li X, Li YS, Li LJ, et al. Overactivated autophagy contributes to steroid-induced avascular necrosis of the femoral head. Exp Ther Med 2017;14:367–72.
[9] She C, Zhu LQ, Zhen YF, et al. Activation of AMPK protects against hydrogen peroxide-induced osteoblast apoptosis through autophagy induction and NADPH maintenance: new implications for osteonecrosis treatment? Cell Signal 2014;26:1–8.
[10] Zhang S, Liu Y, Liang Q. Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS. Mol Med Rep 2018;17:4307–16.
[11] Zhao F, Wang Z, Gao Y, et al. Randomized efficacy trial of conventional, TCM herb, and TEAS on bone marrow supression in patients with small cell lung cancer after initial chemotherapy. Evid Based Complement Alternat Med 2021;2021:2693472.
[12] Shu B, Shi Q, Wang YJ. Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome. Chin J Integr Med 2015;21:656–61.
[13] Jin YX, Wu F, Mao YF, et al. Chinese herbal medicine for osteoporosis: a meta-analysis of randomized controlled trials. J Clin Densitom 2017;20:516–25.
[14] Li JC, Liang XZ, Luo D, et al. Study on the molecular mechanism of BuShenHuoXue capsule in treatment of steroid-induced osteonecrosis of the femoral head. Ann Transl Med 2020;8:1680.
[15] Yuan S, Zhang G, Zhu Y, et al. Neohesperidin ameliorates steroid-induced osteonecrosis of the femoral head by inhibiting the histone modification of IncRNA HOTAIR. Drug Des Devel Ther 2019;13:5419–30.
[16] Jiang X, Chen W, Su H, et al. Puerarin facilitates osteogenesis in steroid-induced necrosis of rabbit femoral head and osteogenesis of steroid-induced osteocytes via miR-34a upregulation. Cytokine 2021;143:155112.
[17] Chen XJ, Shen YS, He MC, et al. Polydatin promotes the osteogenic differentiation of human bone mesenchymal stem cells by activating the BMP2-Wnt/β-catenin signaling pathway. Biomed Pharmacother 2019;112:108746.
[18] Zhang P, Xu H, Wang P, et al. Yougui pills exert osteoprotective effects on rabbit steroid-related osteonecrosis of the femoral head by activating β-catenin. Biomed Pharmacother 2019;120:109520.
[19] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. System Rev 2015;4:1.
[20] Hutton B, Salangi G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.
[21] Chen J, Yue C, He PP, et al. Comparison of clinical outcomes with hip replacement versus PFNA in the treatment of intertrochanteric fractures in the elderly: a systematic review and meta-analysis (PRISMA). Medicine (Baltimore) 2021;100:e24166.
[22] Yue C, Kang P, Pei F. Comparison of direct anterior and lateral approaches in total hip arthroplasty: a systematic review and metaanalysis (PRISMA). Medicine (Baltimore) 2015;94:e2126.
[23] Yue C, Wei R, Liu Y. Perioperative systemic steroid for rapid recovery in total knee and hip arthroplasty: a systematic review and meta-analysis of randomized trials. J Orthop Surg Res 2017;12:100.
[24] Shen P, Wong SP, Yong EL. Sensitive and rapid method to quantify icariin and desmethylicaritin in human serum using gas chromatography-mass spectrometry. J Chromatogr B Analyl Technol Biomed Life Sci 2007;857:47–52.
[25] Li ZR, Sun W, Qu H, et al. Clinical research of correlation between osteonecrosis and steroid. Zhonghua Wai Ke Za Zhi 2005;43:1048–53.
[26] Liu Y, Zong Y, Shan H, et al. MicroRNA-23b–3p participates in steroid-induced osteonecrosis of the femoral head by suppressing ZNF667 expression. Steroids 2020;163:108709.